385 related articles for article (PubMed ID: 22333687)
1. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
4. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
5. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
6. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
7. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
9. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
10. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
11. Biology and natural history of prostate cancer and the role of chemoprevention.
Rosenberg MT; Froehner M; Albala D; Miner MM
Int J Clin Pract; 2010 Dec; 64(13):1746-53. PubMed ID: 21070525
[TBL] [Abstract][Full Text] [Related]
12. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
13. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
14. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
[TBL] [Abstract][Full Text] [Related]
15. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
17. [Natural 5α-reductase inhibitors in treatment of benign prostatic hyperplasia].
Zheng RR; Ouyang QX; Liu ZY; Li LN; Yang L; Wang ZT
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):858-867. PubMed ID: 38621893
[TBL] [Abstract][Full Text] [Related]
18. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
Azzouni F; Zeitouni N; Mohler J
J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
[TBL] [Abstract][Full Text] [Related]
19. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
20. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
